Brief: BridgeBio Says Fortify Phase 3 Study Meets All Primary & Secondary Interim Analysis Endpoints
27/10/2025 11:00
Oct 27 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO REPORTS POSITIVE PHASE 3 RESULTS FOR SMALL MOLECULE BBP-418 IN LGMD2I/R9 FORTIFY STUDY BRIDGEBIO: FORTIFY PHASE 3 STUDY MEETS ALL PRIMARY & SECONDARY INTERIM ANALYSIS ENDPOINTS BRIDGEBIO: TO FILE NDA FOR APPROVAL WITH FDA IN H1 2026 Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels